US FDA approved immunotherapies

PPT Download – US FDA approved immune-checkpoint inhibitors updated 19-Nov-2018

There is no excerpt because this is a protected post.

ESMO 2018 HCC ESMO18 Liver Cancer ESMO2018 hepatocellular carcinoma hepatobiliary cholangiocarcinoma BTC

PPT Download – ESMO18 HCC BTC

There is no excerpt because this is a protected post.

esmo 2018 NSCLC esmo18 lung cancer esmo 2018 non-small cell lung cancer

PPT Download – ESMO18 NSCLC Summary

There is no excerpt because this is a protected post.

Biosimilar Filgrastim Safety Confirmed in Analysis

EP2006, a filgrastim biosimilar, produced safety results equivalent to those observed with referent filgrastim in a combined analysis of 2 Phase 3 breast cancer studies from the United States and Europe.

Read full article (External website)

Immune-Modified Response Criteria in Solid Tumours

Analyzis of atezolizumab data in clinical trials including NSCLC, mUC, RCC and melanoma patients may inform additional modifications to response evaluation criteria

Read full article (External website)

Managing Eating Challenges After Head and Neck Cancer Treatment


English
February 28, 2018
gregguthrie

In this podcast, registered dietitians Annette Goldberg and Maureen Gardner discuss ways to cope with side effects that can make eating difficult due to treatment for head and neck cancer.

Read full article (External website)

trial Finds Survival Benefit With Upfront Atezolizumab Combo for NSCLC

According to findings from the Phase 3 IMpower150 trial, significant improvement was found in overall survival with a treatment regimen of atezolizumab, bevacizumab, carboplatin, and paclitaxel compared to the combination of bevacizumab and chemotherapy alone for patients with advanced nonsquamous non–small cell lung cancer.

Read full article (External website)

FDA Grants Nivolumab/Ipilimumab Priority Review for MSI-H/dMMR Colorectal Cancer

The FDA has granted a priority review to a supplemental biologics license application for nivolumab plus ipilimumab for the treatment of adult patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Read full article (External website)